Annovis Bio (ANVS) Competitors $2.80 -0.08 (-2.60%) Closing price 06/11/2025 03:58 PM EasternExtended Trading$2.88 +0.07 (+2.50%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ENGN, SCPH, CTMX, DRUG, CRGX, IPHA, NBTX, TIL, SOPH, and BTMDShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include enGene (ENGN), scPharmaceuticals (SCPH), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), CARGO Therapeutics (CRGX), Innate Pharma (IPHA), Nanobiotix (NBTX), Instil Bio (TIL), SOPHiA GENETICS (SOPH), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors enGene scPharmaceuticals CytomX Therapeutics Bright Minds Biosciences CARGO Therapeutics Innate Pharma Nanobiotix Instil Bio SOPHiA GENETICS biote enGene (NASDAQ:ENGN) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability. Is ENGN or ANVS more profitable? Annovis Bio's return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -16.69% -14.27% Annovis Bio N/A N/A -311.00% Does the media favor ENGN or ANVS? In the previous week, enGene had 1 more articles in the media than Annovis Bio. MarketBeat recorded 16 mentions for enGene and 15 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.66 beat enGene's score of -0.10 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ENGN or ANVS? 64.2% of enGene shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 10.4% of enGene shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate ENGN or ANVS? enGene currently has a consensus target price of $23.29, indicating a potential upside of 623.16%. Annovis Bio has a consensus target price of $30.25, indicating a potential upside of 978.43%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than enGene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ENGN or ANVS? Annovis Bio received 12 more outperform votes than enGene when rated by MarketBeat users. However, 95.24% of users gave enGene an outperform vote while only 91.43% of users gave Annovis Bio an outperform vote. CompanyUnderperformOutperformenGeneOutperform Votes2095.24% Underperform Votes14.76%Annovis BioOutperform Votes3291.43% Underperform Votes38.57% Which has more risk & volatility, ENGN or ANVS? enGene has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Which has stronger valuation & earnings, ENGN or ANVS? enGene is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.52-2.12Annovis BioN/AN/A-$56.20M-$2.16-1.30 SummaryenGene and Annovis Bio tied by winning 7 of the 14 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$54.66M$6.85B$5.57B$19.81BDividend YieldN/A2.56%5.28%3.84%P/E Ratio-0.638.7827.1735.67Price / SalesN/A255.64410.8846.74Price / CashN/A65.8538.2517.52Price / Book-3.846.557.094.84Net Income-$56.20M$143.93M$3.23B$1.02B7 Day Performance-7.88%3.97%2.91%1.94%1 Month Performance82.26%11.32%9.09%3.03%1 Year Performance-53.87%4.20%31.75%9.73% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.133 of 5 stars$2.81-2.6%$30.25+978.4%-58.5%$54.66MN/A-0.633News CoverageAnalyst ForecastAnalyst RevisionENGNenGene2.6336 of 5 stars$3.98+3.6%$23.29+485.1%-63.2%$202.89MN/A-6.8631Gap UpSCPHscPharmaceuticals4.4331 of 5 stars$3.84+5.5%$14.00+264.6%-0.7%$202.72M$41.98M-2.0230Positive NewsCTMXCytomX Therapeutics4.2946 of 5 stars$2.51-5.3%$5.33+112.5%+89.3%$202.36M$147.56M14.76170Positive NewsDRUGBright Minds Biosciences3.4482 of 5 stars$28.32+9.1%$83.25+194.0%+2,469.4%$199.49MN/A-166.58N/APositive NewsAnalyst RevisionCRGXCARGO Therapeutics2.36 of 5 stars$4.28+0.7%$15.00+250.5%-74.2%$197.35MN/A-1.00116Positive NewsIPHAInnate Pharma3.3001 of 5 stars$2.14-2.2%$11.00+413.8%-22.5%$197.35M$12.62M0.00220Positive NewsGap DownNBTXNanobiotix2.8805 of 5 stars$4.13+0.8%$8.00+93.5%-12.7%$194.85M-$11.61M0.00100News CoverageShort Interest ↓Gap UpTILInstil Bio2.6702 of 5 stars$29.65+10.0%$112.33+278.9%+237.3%$194.47MN/A-2.56410Short Interest ↑High Trading VolumeSOPHSOPHiA GENETICS2.1208 of 5 stars$2.91-3.0%$6.80+133.7%-38.1%$194.06M$67.17M-2.67520News CoverageBTMDbiote3.7133 of 5 stars$3.54+2.3%$8.00+126.0%-35.4%$193.67M$199.38M13.62194 Related Companies and Tools Related Companies enGene Competitors scPharmaceuticals Competitors CytomX Therapeutics Competitors Bright Minds Biosciences Competitors CARGO Therapeutics Competitors Innate Pharma Competitors Nanobiotix Competitors Instil Bio Competitors SOPHiA GENETICS Competitors biote Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
